ABSTRACT
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progressive erosive inflammatory disease of the synovium whose pathogenesis is uncertain. Genetic and environmental factors play a role in the pathogenesis (1) . The prevalence of RA is about 1 % of the population of the world. Females have a higher incidence (3:1) than males (2) . Rheumatoid arthritis is a lifelong disease, although patients can go into remission.
Disease progression ultimately leads to disability, and in its most severe forms, RA is associated with increased mortality (3) . The disease is characterized by synovitis with infiltration of synovial tissue with inflammatory cells which produce various inflammatory cytokines and growth factors, are intimately involved in a variety of symptoms of RA (4,5) . These cytokines, notably tumor necrosis factor-alpha (TNF-α) (6) and interleukin-6 (IL-6) (7) , may promote the development of osteoclasts (8) , which increases bone erosion and systemic bone loss (9) . It has already been demonstrated that reactive oxygen species (ROS) are increasingly produced by inflammatory cells in response to stimulation by pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6. These ROS act as a messenger of the intracellular signaling pathway (nuclear factor-kappa B-"NF-κB"), suggesting that ROS in turn activate inflammatory cells that have a part in the progression of inflammation (10,11) . Generation of hydroxyl radical in RA patients seems able to modify the structure of human IgG, thereby increasing the production of rheumatoid factors, the biologic hallmark of the disease (12) . ROS are highly reactive chemical species, which are formed during normal aerobic metabolism in cells and after the activation of phagocytes during infection or inflammation (13) . Cells are normally protected from ROS-induced damage by a variety of endogenous scavenging proteins, enzymes and chemical compounds that constitute the endogenous antioxidant systems (14 ) . It has been reported that ROS destroy antioxidant systems (in fact antioxidant systems are impaired in RA) and that RA patients are thus exposed to oxidant stress and lipid peroxidation because of the reduced antioxidant defence system (15) .
Recent studies indicated that reactive oxygen species (ROS) play an important role in the development of RA, in that in these patients the antioxidant system is impaired and peroxidation reactions are accelerated (1) . Epidemiological studies have shown that RA occurs in previously healthy subjects who have low levels of circulating antioxidants, implying a pathogenic role of increased oxidative stress in the development of RA. Targeting of ROS could have a therapeutic value in arthritis as a strategy to reduce the development of inflammation. Many therapeutic trials have assessed the clinical value of antioxidants administration in RA in an effort to restore a normal pool of ROS scavengers (16,17) . Alpha lipoic acid (also known as thioctic acid), has a high reactivity with oxygen free radicals and potential activity as a strong free radical scavenger. Alpha lipoic acid (α-LA) has generated considerable clinical interest as a potent scavenger of reactive oxygen species as it quenches singlet oxygen, hydroxyl radical and hypochlorus acid (18) . Alpha lipoic acid is considered as a unique metabolic antioxidant as this small molecule is soluble in both water and fat. This is significant because water soluble antioxidant nutrients (vitamin C for example) are found within the cell and fat soluble antioxidants (vitamin E for example) are found on the cell membrane. Because Alpha lipoic acid (α-LA) works both inside the cell and at the membrane level, it can give a dual protection (19) .
Lipoic acid contains two thiol groups, which may be oxidized or reduced; both forms of lipoic acid are antioxidants (20) . Most antioxidant substances can be oxidized and reduced and usually can only act as antioxidants when they are in their reduced form. Alpha lipoic acid is unique in that both its oxidized and reduced forms possess antioxidant properties. Alpha lipoic acid is able to inhibit free radical reactions from such diverse sources as those generated from the body's own metabolism or from various environmental sources (21) . Alpha lipoic acid is a naturally occurring compound that is synthesized in small amounts by plants and animals; including humans (22,23) . In humans, α-LA is synthesized in liver and other tissues and is also obtained from both animal and plant sources in the diet. It is readily absorbed from the diet. α-LA is found in animal tissues with extensive metabolic activity such as heart, liver, and kidney. The plant sources of α-LA, listed from highest to lowest, are spinach, broccoli, tomatoes, peas, brussel sprouts, and rice bran (20) . Immunization of rats with collagen II (CII) leads to development of arthritis "the collagen-induced arthritis model for RA" (24) . Rat type II collagen (CII)-induced arthritis (CIA) is commonly used as an animal model of RA because it includes some of the clinical and pathological features similar to those of human RA. It is usually used to investigate mechanisms relevant to RA as well as new antiarthritic treatments (25) .
Aim of the work:
The purpose of the present study was to assess effect of alpha-lipoic acid (α-LA) to attenuate the development of rheumatoid arthritis in rat model of collagen II-induced arthritis (CIA). Clinical and biochemical assessment of many arthritic parameters have been studied in this work to evaluate the potentially protective effect of α-LA administration in CIA rats.
MATERIALS & METHODS

Animals:
Thirty healthy female albino rats, their body weight ranged 150-170 g were included in the present study. All animals were conditioned at room temperature and natural photoperiod for 1 week before the start of the experiment. A commercial balanced diet and tap water were provided. The duration of experiment was 42 days.
Animals grouping:
Rats were randomly divided into 3 groups (10 rats each) as the following:
1-Control group: group I 2-Collagen II-induced arthritis (CIA) group (group II): injected with bovine collagen II as described by Terato et al., (26) . 3-CII + alpha lipoic acid (α-LA ) -treated group (CIA+ α-LA group): group III. Rats of group III were injected by CII, and received α-LA daily in a dose of 100 mg/kg/day/ intraperitoneally as mentioned by Lee et al., (1) , from the beginning of CII injection for 42 days. α-LA was purchased from Sigma Chemical (St. Louis, MO, USA).
Methods:
I-Induction of Collagen II-induced arthritis (CIA): CIA was induced as previously described by Terato et al., (26) . Briefly, collagen type II (CII) was dissolved in 0.01 N acetic acid and emulsified in an equal volume of complete Freund's adjuvant (CFA) containing 1mg/ml heat-killed Mycobacterium tuberculosis (SigmaAldrich). Rheumatoid arthritis was induced by the initial immunization with100μg/100μl emulsion by an intradermal injection in the base of the tail. Twenty one days later after the initial immunization, rats received a booster intradermal injection of bovine CII.
-Animals of different groups were sacrificed under light anesthesia at the end of the experiment. Blood samples from all groups were collected from the orbital vein in heparinized tubes and were centrifuged at 5000 rpm for 10 min for plasma separation. Plasma samples were divided into aliquots and kept at -40 o C until biochemical analysis.
II-Clinical evaluation of arthritis:
All rats of group II and group III were inspected every third day after CII injection to assess the development and severity of arthritis. Each paw of all rats was inspected for signs of inflammation as swelling, erythema or both. Also, signs of arthritis in the joints (namely, wrist, knee and ankle joints) as swelling, tenderness and movement limitation had been assessed.
III-Follow up of body weight:
Changes in body weight were monitored with electronic scale for rats of all groups. Body weight for every rat in each group was evaluated 5 times: at the first day of the experiment (day 0), 2 weeks after induction of arthritis (day 15), just before injection of the booster dose (day 21), one week after booster dose (day 28) and finally at the end of the experiment (day 42).
IV-Biochemical analysis
In this study, measurement of markers of oxidative stress and inflammation has been done. So, the study measured the following parameters:
1. All values were expressed as the mean ± standard error (M ± SE). The statistical significance between two groups was analyzed by student t-test. P value <0.05 was considered to represent a significant difference. Spearman's correlation test was also used to study correlation between groups with a range from -1 to 1.
RESULTS
I-Clinical assessment of collagen IIinduced arthritis (CIA) and role of α-LA:  Rats of group II (CIA group): By the end of the study, it was observed that arthritis had been successfully created in all rats of group II. Signs of arthritis were varied from mild swelling and/or redness of the paw or one digit till severe arthritis affecting most of the joints, led to limitation of all movement of the rat. The initial signs of arthritis in most animals of group II were evident at day 13, all animals gave signs of arthritis at day 18; they were maintained arthritic until the end of the experiment. The first manifestation of the disease was mild swelling and/or redness of the paw, followed by erythema and swelling of one or more joints, followed by involvement of most of the joints. The course of the disease was progressive. Four days after injection of the booster dose, the intensity of arthritis increased markedly in all rats of group II, nearly, all rats can not move from severity of the pain and the swelling of the joints.  Rats of group III (CII+ α-LA):
Rats of group III showed marked attenuation in the incidence of development of arthritis (less than half of the rats 
II-Follow up of body weight:
In the first 2 weeks, the normal gain in body weight was comparable in all groups, and no significant differences were seen between them. Rats of control group (group I) showed gradual, progressive weight gain through out whole duration of the experiment. By end of the study, control rats gained more than 25% of their original weight at the beginning of the study. Rats of Group II (CIA group) began to show less weight gain than the control rats after 2 weeks. By the day 21, a significant decrease in body weight (p<0.01) was observed in CIA rats compared with the control rats. After that, the mean body weight of CIA group showed progressive gradual decrease continued till end of the experiment (day 42). The highest body weight loss was significant at 4 and 6 weeks in the CIA group, in comparison with the control group (p<0.001).
Daily injection of rats of group III with α-LA 100 mg/kg/day significantly attenuated the loss in body weight in this group relative to weights of rats of group II. Rats of group III exhibited slightly significant loss of normal weight gain at the onset of arthritis (day 21) as compared to control group (p<0.05), but slowly regained weight during the following days. At the end of the study, group III showed non significant difference in their body weight (p>0.05) in comparison to control group. (Table  1) . III-Effect of α-LA on plasma levels of lipid peroxides, nitric oxide and superoxide dismutase in CIA rats: Table ( 2) showed that plasma levels of oxidative stress markers (lipid peroxides and nitric oxide) were highly significantly increased (p<0.001) in CIA group (group II) as compared to the control group (group I). Additionally, plasma level of antioxidant enzyme, superoxide dismutase (SOD) was significantly decreased (p<0.001) in CIA rats as compared with those of control rats.
6 weeks injection of α-LA to animals of group III caused a significant reduction in levels of lipid peroxides (p<0.001) and nitric oxide (p<0.01) when compared by group II. Also, plasma level of SOD showed highly significant increase (p<0.001) in rats of group III as compared to those of group II.
Comparing mean values of oxidative indices parameters of group III with those of the control values, LPO and S.O.D showed non significant difference (p>0.05), but NO level still showing significant increase (p<0.5) as compared to control values (Table 2) . IV-Effect of α-LA on plasma levels of inflammatory and proinflammatory mediators in CIA rats:
Animals of group II (CIA) showed very highly significant increase in inflammatory markers, prostaglandin and C-reactive protein (PGE2 and CRP) 6 weeks after initial immunization with CII as compared with group I (p<0.001 for each). Animals of group III (CII+ α-LA treated group) showed highly significant reduction in inflammatory markers as compared with group II (p<.001 for each) (Table 4) .
Plasma level of TNF-α was found to be significantly higher (p<0.001) in group II than group I. Animals of group III (CII+ α-LA treated group) showed significant reduction in TNF-α as compared with group II (p<.001).
Comparing levels of PGE2, CRP and TNF-α of group III with those of control one showed non significant (p>0.5) change for CRP and TNF-α, but PGE2 still showed significant (p<0.5) increase (Table 3) . V-Correlation between plasma level of TNF-α and changes in body weight in CIA group (group II):
Decrease body weight of group II rats showed very highly significant (P<0.001) positive correlation with the increase in plasma level of TNF-α of the same group, indicating the possible role of this pro-inflammatory cytokine in decreasing body weight after induction of arthritis (Table 4) . recorded that CII-induced arthritis is a model of rheumatoid arthritis that induces cachexia. Arthritis decreases food intake both due to marked restriction of movement of the animal due to severe pain and joint swelling as well as due to anorexia associated with chronic inflammatory condition. They suggested that in chronic arthritis, decrease adipose tissue weight is secondary to a reduced adipose lipogenesis, and this effect is not mainly due to the decrease in food intake. However, the mechanism by which arthritis reduces fat stores is not well known. In 2006, Granado et al., (42) reported that fat mass loss in rheumatoid arthritis can be secondary to an increase in lipolysis and/or a decrease in lipogenesis. Another study reported that induced arthritis decreased body weight due to enhanced protein breakdown as well as decreased food intake (43) . Data indicate that arthritis-induced decrease in body weight is not only due to a decrease in food intake, but also related to metabolic alterations that result in a dramatic decrease of adiposity. In 2007, Lacasa et al., (44) postulated that prolonged elevation of cytokines in adipose tissue due to inflammatory reactions and decrease food intake can be the main causes of body weight reduction in chronic arthritis.
Among these proinflammatory cytokines, TNF-α has been reported to decrease lipogenesis.
The present study showed that intraperitoneal injection of rats of group II with collagen type II (CII) resulted in a significant increase in reviewed that as there is a growing body of evidence indicates that ROS perpetuates the chronic inflammatory state associated with RA, thus, it follows that one approach to treating RA is to remove these reactive oxygen species (ROS). So, a number of antioxidants have been tested in CIA model in the attempt to limit the oxidative damage. Alpha lipoic acid has generated considerable clinical interest as a potent natural antioxidant agent (59) . In 2007, Lee et al (1) proved that α-LA has a role to prevent lipid peroxidation and to support antioxidant system against oxidative damage in experimental model of arthritis. Moreover, α-LA inhibited bone destruction in vivo and osteoclastogenesis in vitro
In the current study, daily administration of α-LA daily from the beginning of CII injection for 42 days to rats of group III induced significant reduction of plasma level of LPO and NO as well as a significant increase in plasma level of SOD in rats of group III as compared with group II. These findings indicate that α-LA could decrease lipid peroxidation and free radical formation and lead to a substantial recovery of one of the major antioxidant enzymes; SOD, thus limiting oxidative damage and decrease ROS formation, so, it could be considered as a protective agent against joint injury occurring in CIA. These results are in agreement with previous studies which recorded significant reduction of oxidative stress markers with marked increase in antioxidant levels in experimental model of arthritis after administration of α-LA (48,60,61,62) . Superoxide dismutase (SOD), which is a known antioxidant agent has been proved to have an antiinflammatory activity in several animal models of induced inflammation as in CIA rats. It was claimed that the SOD's antiinflammatory action is through prevention of formation of superoxide-dependent chemotactic activity (63) . That action prevents the accumulation of inflammatory cells at the site of a potential lesion; thereby preventing all neutrophil-mediated cytotoxic events (64) . Various studies showed that α-LA enhances SOD activity in rheumatoid arthritis models (64,65,66) . So, in the present study, increase level of SOD after administration of α-LA could be one mechanism by which α-LA exerts its activity in CIA rats.
Popa et al., (2005)
(67) reviewed that rheumatoid arthritis (RA) is characterized by high concentrations of pro-inflammatory cytokines such as tumor necrosis factor a (TNF-α), IL6, and interferon, especially in the synovial fluid but also in the circulation. The present study revealed an increase in serum level of TNF-α in CIA rats (group II). Additionally, the study revealed suppressing effect of lipoic acid on TNF-α in rats of group III. This was in accordance with the finding of Tastekin et al., (2007) (49) who recorded increased serum level of TNF-α in CIA rats which revealed the key role of this pro-inflammatory cytokine in the pathogenesis of rheumatoid arthritis. Furthermore, they recorded significant decrease of TNF-α serum level with α-LA treatment. Cytokines as TNF-α and IL-6 appear to be critically involved in the initiation and perpetuation of RA.
These pro-inflammatory cytokines are considered to play a prominent role in RA pathogenesis by modulating cell migration, T and B cell activation, cartilage destruction, and synovial proliferation. Also, TNF-α induced nuclear factor-kappaB (NF-κB) activation which increase the severity of the inflammation in arthritis (68,69,70) . Recent advances in arthritis treatment mainly focus on anti TNF-α agents (71,72) . Regulation of cytokine levels in patients with RA may also be a novel approach to the treatment of these diseases They demonstrated that α-LA decreased the severity of inflammation and prevented joint destruction in collagen-induced arthritis mouse model via NF-κB down regulation. They suggested that amelioration of joint disease when treated with α-LA was associated with reduction in oxidative stress, as well as inhibition of TNF-α induced NF-κB activation. From these findings, it could be exhibited that the possibility of a therapeutic effect of α-LA in established RA by suppressing the release of this pro-inflammatory cytokine.
In 2009, Shay et al., (75) reported that recent therapeutic strategies in RA aimed at mitigating oxidant production and oxidative damage. Reduction of severity of collageninduced arthritis in mice by α-LA treatment is due to the reduction of inflammatory cytokines like TNF-α, and partial inhibition of NF-κB binding to DNA. Also, α-LA inhibited osteoclast formation, suggesting that α-LA may be useful in prevention of bone erosion and joint destruction in rheumatoid arthritis (76) . The present study showed highly significant increase in inflammatory markers e.g., prostaglandin and Creactive protein (PGE 2 and CRP) 6 weeks after initial immunization with CII in rats of group II as compared with group I. Additionally, treatment of rats of group III with α-LA showed significant reduction in inflammatory markers as compared with group II. These findings were in accordance with previous findings of other investigators (23, 37, 49, 77, 78) . The antiinflammatory properties of α-LA in humans have been investigated in a study carried by Sola et al., (2005) (37) . It showed a significant decrease in serum TNF-α, interleukin-6 and other inflammatory markers following 4 weeks of supplementation with α-LA (300 mg/day). Moreover, in 2007, Smolen et al., (79) reviewed that in rheumatoid arthritis there is a release of numerous pro-inflammatory mediators such as prostaglandins (PGs) and nitric oxide (NO).
Conclusion:
In conclusion, our study revealed that RA is a multifaceted disease for which additional treatments are still needed. The study showed that α-LA has a role to prevent oxidative stress and to support antioxidant system against oxidative damage in this experimental arthritis model. Also, amelioration of joint damage in CIA rats by α-LA was associated with inhibition of inflammatory process by lowering plasma level of TNF-α, prostaglandin and C-reactive protein. 
